Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors

Mithramycin (MTM), a cytotoxic compound, is currently being investigated for its anti-angiogenic activity that seems to be mediated through an inhibition of the transcription factor SP1. In this study we evaluated its anti-myeloma effects in the syngenic 5TGM1 model in vitro as well as in vivo. In v...

Descripción completa

Detalles Bibliográficos
Autores principales: Otjacques, Eléonore, Binsfeld, Marilène, Rocks, Natacha, Blacher, Silvia, Vanderkerken, Karin, Noel, Agnès, Beguin, Yves, Cataldo, Didier, Caers, Jo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646989/
https://www.ncbi.nlm.nih.gov/pubmed/23667526
http://dx.doi.org/10.1371/journal.pone.0062818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646989/
https://www.ncbi.nlm.nih.gov/pubmed/23667526
http://dx.doi.org/10.1371/journal.pone.0062818

Ejemplares similares